55.610USD+55.610æéå€ååŒÂ 07/29, 20:00 (ET)
4.44BæäŸ¡ç·é¡
49.91çŽè¿12ã¶æPER
äž»èŠããŒã¿
55.600å§å€
56.630é«å€
740.19Kåºæ¥é«
49.91çŽè¿12ã¶æPER
42.74äºæ³PER
--çŽè¿12ã¶æé
åœ
0.93%売買å転ç
55.610忥çµå€
54.715å®å€
30.76M売買代é
183.96æ ªäŸ¡åçç
3.30PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
0.00%çŽè¿12ã¶æé
åœå©åã
6.40%ç·è³ç£å©çç
50.71052é±é«å€
1.08åºæ¥é«æ¯ç%
24.14MçŽå©ç
79.79Mæ ªåŒæ°
1.11501æ ªåœããå©çïŒEPSïŒ
1.98ããŒã¿å€
6.93%èªå·±è³æ¬å©çç
22.61052é±å®å€
3.44%æ¯ãå¹
72.32%ç²å©çç
4.44BæäŸ¡ç·é¡
-2.74ãªã¹ã¯ãªã¿ãŒã³
2.78%ãªã¹ã¯ç
é貚: USD æŽæ°æå»: 2026-07-28 äž»èŠã€ã³ãµã€ã
Veracyte Incã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯æ¯èŒçéåžžã«å¥å
šã§ããæé·ã®å¯èœæ§ã¯é«ãã§ããããªã¥ãšãŒã·ã§ã³ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸãããã€ãªãã¯ãããžãŒ & å»çç ç©¶æ¥çã§ã®é äœã¯385äž23äœã§ããæ©é¢æè³å®¶ä¿æçã¯éåžžã«é«ãã§ããéå»1ãæéã«è€æ°ã®ã¢ããªã¹ããè²·ããšè©äŸ¡ããæé«ç®æšæ ªäŸ¡ã¯57.83ãšãããŠããŸããäžæçã«ã¯ãæ ªäŸ¡ã¯äžæãã¬ã³ããšäºæ³ãããŸããæ ªåŒåžå Žã§ã®ããã©ãŒãã³ã¹ã¯ãã®1ãæã§äœèª¿ã§ããããå瀟ã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯å
調ã§ããæ ªäŸ¡ã¯æ¯æç·ã𿵿ç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
Veracyte Incã®ã¹ã³ã¢î°î°
ãµããŒãã©ã€ã³ãšã¬ãžã¹ã¿ã³ã¹ã©ã€ã³

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
éåžžã«äœã
éåžžã«é«ã
Veracyte Incã®æ³šç®ãã€ã³ã
匷ã¿ãªã¹ã¯
Veracyte Inc ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
åçäºæž¬î
匷åè²·ã
è²·ã
äžç«
売ã
匷å売ã
Ionis Pharmaceuticals Inc
IONS
26
ææšî
ææš
売ã(3)
äžç«(2)
è²·ã(0)
ç§»åå¹³å
売ã(3)
äžç«(0)
è²·ã(3)
è²¡åææšî
EPS

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Veracyte Incã®äŒæ¥æ
å ±î
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
äŒæ¥ã³ãŒãVCYT
äŒæ¥åVeracyte Inc
æé«çµå¶è²¬ä»»è
ãCEOãStapley (Marc A)
ãŠã§ããµã€ãhttps://www.veracyte.com/
æ ªäž»çµ±èšî
ãããã質å
Veracyte IncïŒVCYTïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îVeracyte IncïŒVCYTïŒã®çŸåšã®æ ªäŸ¡ã¯55.65ã§ãã
Veracyte Incã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îVeracyte Incã®ãã£ãã«ãŒã·ã³ãã«ã¯VCYTã§ãã
Veracyte Incã®52é±é«å€ã¯ãããã§ããïŒ
îVeracyte Incã®52é±é«å€ã¯50.71ã§ãã
Veracyte Incã®52é±å®å€ã¯ãããã§ããïŒ
îVeracyte Incã®52é±å®å€ã¯22.61ã§ãã
Veracyte Incã®æäŸ¡ç·é¡ã¯ãããã§ããïŒ
îVeracyte Incã®æäŸ¡ç·é¡ã¯4.44Bã§ãã
Veracyte Inc (VCYT) ã®çŸåšã®è©äŸ¡ã¯ãè²·ããããããŒã«ãããã売ããã®ã©ãã§ããïŒ
îã¢ããªã¹ãã«ãããšãVeracyte IncïŒVCYTïŒã®ç·åè©äŸ¡ã¯è²·ãã§ãç®æšæ ªäŸ¡ã¯57.83ã§ãã
Veracyte Inc (VCYT) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îVeracyte IncïŒVCYTïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯0.84ã§ãã